Atypical Pneumonia
Conditions
Keywords
Mycoplasma pneumoniae, Macrolide-resistance, Children
Brief summary
A randomized clinical trial comparing treatment effectiveness of azithromycin and doxycycline for pediatric Mycoplasma pneumonia.
Detailed description
Mycoplasma pneumoniae accounts for 10-30% of community-acquired pneumonia (CAP) in children. Proportionally, M. pneumoniae has become the most important pathogen for childhood pneumonia after the widespread use of Streptococcus pneumoniae vaccines. M. pneumoniae is routinely treated with antibiotics, and the macrolides antibiotics are the drug of choice for M. pneumonia infection. However, macrolide-resistance rates have increased to 20 and 100% in Asia. In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. The evolution and spreading of Mycoplasma in Taiwan and different countries are unknown. While the macrolide-resistance is increasing, the optimal therapy remains unclear. Both tetracyclines and fluoroquinolones showed promises in treating macrolide-resistant M. pneumoniae in adults. However, their use in children is not recommended due to safety concerns. Recently, evidence are accumulating that doxycycline, unlike other tetracyclines, does not cause staining of teeth. In the current study, the investigators are going to carry out a randomized control trial to compare the efficacy and safety of doxycycline against macrolide-resistant M. pneumoniae.
Interventions
DRUGDoxycycline
Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
DRUGAzithromycin
Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Sponsors
National Taiwan University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children aged 0-18 years, admitted due to lower respiratory tract infections. Mycoplamsa pneumonia is diagnosed. * The diagnosis is made within 72 hours after fever onset. * The patient and his/her guardians are willing to participate the study and able to follow the instruction.
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Defervescence | Up to 10 days | The timing (days) when fever subsides after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospital stay | Up to 2 weeks | The length of hospitalization |
Countries
Taiwan
Contacts
Primary ContactLi-Min Huang, MD, PhD
Outcome results
None listed